help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Finch, A. R.
Right arrow Articles by McArdle, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Finch, A. R.
Right arrow Articles by McArdle, C. A.
The Journal of Clinical Endocrinology & Metabolism Vol. 89, No. 4 1823-1832
Copyright © 2004 by The Endocrine Society

Signaling and Antiproliferative Effects of Type I and II Gonadotropin-Releasing Hormone Receptors in Breast Cancer Cells

Ann R. Finch, Lisa Green, James N. Hislop, Eamonn Kelly and Craig A. McArdle

Wellcome Laboratories for Integrative Neuroscience and Endocrinology (A.R.F., L.G., C.A.M.) and Department of Pharmacology (E.K.), University of Bristol, Bristol, BS1 3NY, United Kingdom; and University of California at San Francisco (J.N.H.), San Francisco, California 94143

Address all correspondence and requests for reprints to: Dr. Craig A. McArdle, Wellcome Laboratories for Integrative Neuroscience and Endocrinology, University of Bristol, Whitson Street, Bristol, BS1 3NY United Kingdom. E-mail: craig.mcardle{at}bris.ac.uk.

GnRH receptors (GnRH-Rs) mediate direct antiproliferative effects on hormone-dependent cancer cells. GnRH-Rs can be grouped according to ligand specificity (for GnRH-I and -II), and there is evidence that type II GnRH ligands and/or receptors can inhibit proliferation. Type I GnRH-Rs (e.g. human and sheep) lack the C-terminal tails found in other G protein-coupled receptors including type II GnRH-Rs (e.g. Xenopus; XGnRH-R). This underlies the remarkable resistance of type I GnRH-Rs to desensitization and may be important for chronic effects on proliferation. To test this, we have compared the antiproliferative effects of GnRH-Rs expressed in MCF7 breast cancer cells using recombinant adenovirus (Ad). Endogenous GnRH-Rs were not detected, but infection with Ad-expressing sheep GnRH-Rs (sGnRH-R) facilitated proliferation inhibition by Buserelin, and maximum inhibition required only 10,000–20,000 sGnRH-Rs. XGnRH-Rs were much less efficient at inhibiting proliferation and were internalized faster than sGnRH-Rs. Thus, the type II GnRH-R is less efficient at inhibiting proliferation, presumably because it is rapidly desensitized and/or internalized. Moreover, comparisons of human GnRH-R, sGnRH-R, and XGnRH-R, as well as chimeric receptors (type I GnRH-Rs with C-terminal tails from XGnRH-Rs), revealed that C-terminal tail addition increases receptor expression and thereby increases the efficiency with which the vector facilitates the antiproliferative effect.

This work was supported by the Wellcome Trust for project grant support (062918).

Abbreviations: [3H]IPx, [3H]Inositol phosphate; Ad, adenovirus; AR, adrenergic receptor; cGnRH-II, chicken GnRH-II; FCS, fetal calf serum; GnRH-R, GnRH receptor; GPCR, G protein-coupled receptors; hGnRH-R, human GnRH-R; h.XGnRH-R, hGnRH-R with an added XGnRH-R C-terminal tail; PLC, phospholipase C; PSS, physiological salt solution; sGnRH-R, sheep GnRH-R; s.XGnRH-R, sGnRH-R with an added XGnRH-R C-terminal tail; XGnRH-R, Xenopus GnRH-R.




This article has been cited by other articles:


Home page
J EndocrinolHome page
A. R Finch, K. R Sedgley, C. J Caunt, and C. A McArdle
Plasma membrane expression of GnRH receptors: regulation by antagonists in breast, prostate, and gonadotrope cell lines
J. Endocrinol., February 1, 2008; 196(2): 353 - 367.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
K. R Sedgley, A. R Finch, C. J Caunt, and C. A McArdle
Intracellular gonadotropin-releasing hormone receptors in breast cancer and gonadotrope lineage cells
J. Endocrinol., December 1, 2006; 191(3): 625 - 636.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. J. Caunt, A. R. Finch, K. R. Sedgley, L. Oakley, L. M. Luttrell, and C. A. McArdle
Arrestin-mediated ERK Activation by Gonadotropin-releasing Hormone Receptors: RECEPTOR-SPECIFIC ACTIVATION MECHANISMS AND COMPARTMENTALIZATION
J. Biol. Chem., February 3, 2006; 281(5): 2701 - 2710.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
K. Wada, L. Hu, N. Mores, C. E. Navarro, H. Fuda, L. Z. Krsmanovic, and K. J. Catt
Serotonin (5-HT) Receptor Subtypes Mediate Specific Modes of 5-HT-Induced Signaling and Regulation of Neurosecretion in Gonadotropin-Releasing Hormone Neurons
Mol. Endocrinol., January 1, 2006; 20(1): 125 - 135.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
A. Nagy and A. V. Schally
Targeting of Cytotoxic Luteinizing Hormone-Releasing Hormone Analogs to Breast, Ovarian, Endometrial, and Prostate Cancers
Biol Reprod, November 1, 2005; 73(5): 851 - 859.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2004 by The Endocrine Society